The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes

Table 4

The LOCF analysis with HAM-D₁₇.

HAM-D17	Active T-PEMF	Sham T-PEMF
	(𝑁=21)	(𝑁=19)
Baseline	21.29 (4.0)	21.62 (3.6)
week 1	17.33 (5.1)*	19.58 (3.3)
week 2	15.05 (3.2)*	17.63 (4.9)
week 3	14.10 (4.5)**	17.68 (4.9)
week 4	12.67 (5.6)**	17.79 (4.0)
week 5	11.38 (6.5)**	16.68 (4.4)

* 𝑃≤.05.
** 𝑃≤.01.